Therapeutics / Pharmaceutical / Biotech / Industrial / BioTech / Pharmaceuticals / National blog main / National top stories / Texas / Texas blog main / Texas top stories / Actavis / Allergan / austin / Deerfield Management / diabetes / Douglas Baum / Drugs / Durata Therapeutics / G-Pen / glucogen / medical devices / Paul Edick / Redmile Group / Robert Faulkner / Sabby Management / The McNair Group / Venture Capital / Xeris Pharmaceuticals

Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round

Posted on: Jan 11, 2017   |   Posted by: Biotech Mag

Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round

Austin -Xeris Pharmaceuticals, an Austin biotech, has raised $41 million in a Series C funding round and named a new CEO. Paul Edick has replaced Douglas Baum, as president and...

Continue reading ...



Other Posts from Biotech Mag